There is a growing trend in the use of small, portable extracorporeal membrane oxygenation (ECMO) systems for hemodynamic support. In years past, ECMO systems were a tool of the operating room, primarily for bypass surgery. Older systems required a perfusionist to watch the machine 24 hours a day while it was in operation. Today’s ECMOs use consoles that are much easier to use and do not require a full-time person to monitor. Also, as the technology has been miniaturized, simplified and now uses a percutaneous access system, ECMOs are being used outside the OR, including the cath lab, when a large amount of support is needed that cannot be provided by IABPs or pVADs. 

 

Since the 1970s, intra-aortic balloon pumps (IABPs) have been the gold standard of minimally invasive hemodynamic support, but more recently developed percutaneous ventricular assist devices (pVAD) are offering an alternative. Clinical data shows pVADs offer more support than IABPs, but their much higher price tag currently restricts their use to niche applications, usually after an IABP fails to deliver enough support. 

Live demonstration, transmission or recording of transcatheter aortic valve replacement (TAVR) has been found feasible and safe, even for the typically high-risk patients who undergo the procedure. Results of the VERITAS late-breaking clinical trial, presented at the SCAI 2013 Scientific Sessions, confirmed via comparison of on- and off-camera case studies that recording procedures did not pose any additional risk or complications to patients. 

 

A new method of dynamic, personalized intravenous hydration significantly reduces the percentage of contrast-induced kidney injury from image-guided cardiovascular procedures, according to the results of the POSEIDON clinical trial presented as a late-breaking clinical trial at the SCAI 2013 Scientific Sessions.

For patients who received stents to restore blood flow through the main arteries supplying blood to the brain, inflating a tiny balloon inside the arteries after implantation of the stent  reduced restenosis, or repeat blockages, of the treated arteries, making them less likely to reclose. Modifying the order in which carotid stenting and balloon angioplasty is performed could also alter risk of stroke complications, according to the investigators of the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) sub-study presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. 

 

The impact of pediatric interventional cardiology has never been stronger, nor the need for organized, high-quality training greater, says Frank F. Ing, M.D., FSCAI, who delivered the annual Mullins Lecture at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. He made the case that advances in technology and growth in the profession mean that now is the time to take training to the next level.

Boston Scientific Watchmen Left Atrial Appendage Closure Atrial Fibrillation

May 13, 2013 — Boston Scientific reports that the four-year follow-up data from the PROTECT AF clinical trial demonstrated the Watchman left atrial appendage (LAA) closure device was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolization.

Biosense Webster Inc. announced the first patient has been enrolled in the reMARQable clinical study. ReMARQable will assess the safety and efficacy of the use of the nMARQ Pulmonary Vein Isolation System to treat paroxysmal atrial fibrillation. Atrial fibrillation (Afib) is a heart rhythm disorder that affects approximately 20 million people worldwide.

 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now